Education
About Us
Working with TipRanks
Follow Us
MetaVia (MTVA)
NASDAQ:MTVA
MTVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.56 - $4.32
Previous CloseN/A
Volume36.62K
Average Volume (3M)128.84K
Market Cap
$15.24M
Enterprise Value-$7.66M
Total Cash (Recent Filing)$17.59M
Total Debt (Recent Filing)$98.00K
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Nov 17, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding24,197,810
10 Day Avg. Volume38,348
30 Day Avg. Volume128,836
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit547.02
Enterprise Value/Ebitda0.48
Forecast
1Y Price Target
$3.00Price Target Upside361.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Cardiovascular SafetyDA-1726 did not exhibit any clinically significant increases in heart rate or QTcF intervals up to a dose of 32mg over the 4-week administration period, highlighting its favorable cardiovascular safety profile.
Obesity TreatmentMetaVia's DA-1726 is potentially superior in weight loss with a better tolerability profile compared to other treatments in the same space.
Safety ProfileDA-1726 has shown initial weight loss and positive safety results with no plateau effect in its ongoing study.
Bears Say
Stock ReactionMTVA shares were down 56% on the news, which is viewed as an overreaction on what was only an early-stage study.
Study PhaseMTVA reported top-line data from its 4-week Phase 1 multiple ascending dose (MAD) study of DA-1726 in healthy participants and the stock was down sharply on the news, which we believe was an overreaction that did not take into account the totality of the data.
MetaVia News
MTVA FAQ
What was MetaVia’s price range in the past 12 months?
MetaVia lowest stock price was $0.56 and its highest was $4.32 in the past 12 months.
What is MetaVia’s market cap?
MetaVia’s market cap is $15.24M.
When is MetaVia’s upcoming earnings report date?
MetaVia’s upcoming earnings report date is Nov 17, 2025 which is in 80 days.
How were MetaVia’s earnings last quarter?
MetaVia released its earnings results on Aug 07, 2025. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.223 by -$0.037.
Is MetaVia overvalued?
According to Wall Street analysts MetaVia’s price is currently Undervalued.
Does MetaVia pay dividends?
MetaVia does not currently pay dividends.
What is MetaVia’s EPS estimate?
MetaVia’s EPS estimate is -0.23.
How many shares outstanding does MetaVia have?
MetaVia has 24,197,810 shares outstanding.
What happened to MetaVia’s price movement after its last earnings report?
MetaVia reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.223. Following the earnings report the stock price went up 3.226%.
Which hedge fund is a major shareholder of MetaVia?
Currently, no hedge funds are holding shares in MTVA
Company Description
MetaVia
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
MTVA Stock 12 Month Forecast
Average Price Target
$3.00
▲(361.54% Upside)
Technical Analysis
Palatin Technologies
―
Evogene
―
TransCode Therapeutics
―
Silexion Therapeutics
―
Apollomics
―
Ownership Overview
42.76% Insiders
0.41% Mutual Funds
0.04% Other Institutional Investors
56.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---